AbbVie: Rinvoq And Skyrizi Will Bridge US Humira Sales Erosion Through 2025
Executive Summary
Continuing its longstanding effort to assure investors about growth past Humira’s US patent expiry in 2023, the pharma outlined label-expansion and market share plans for its two newer immunology drugs.
You may also be interested in...
J.P. Morgan Day 2: Pharma Offers (Some) Views On Drug Pricing Reform
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Novartis explains its PD-1 deal; Biogen partners with Apple; Sanofi and Merck discuss business development priorities; and why AbbVie is confident it can grow without relying on deals.
J.P. Morgan Day 2: Pharma Offers (Some) Views On Drug Pricing Reform
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Novartis explains its PD-1 deal; Biogen partners with Apple; Sanofi and Merck discuss business development priorities; and why AbbVie is confident it can grow without relying on deals.
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the past week's major events in the global biopharma industry, as brought to you by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Need a specific report? 1000+ reports available
Buy Reports